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‘Low-dose’ dopamine is frequently used in intensive care
units (ICU) for its presumed renoprotective effects, but
prospective and retrospective studies have so far not proven
prevention or amelioration of renal injury. Data on renal
perfusion following dopamine infusion are limited. In order
to circumvent the problem of patient heterogeneity in the
ICU setting, we used a crossover design in a prospective,
double-blind randomized controlled study to investigate the
effect of ‘low-dose’ dopamine on renal resistance indices,
as determined by Doppler ultrasound. Forty patients, 10
without and 30 with acute renal failure (ARF, defined as
doubling of baseline creatinine or an increase above
2 mg/dl), were included. Dopamine (2 lg/kg min) or placebo
was given intravenously in alternating sequence for four
subsequent periods of 60 min, starting randomly with either
dopamine or placebo. Resistive (RI) and pulsatility index (PI)
were closely correlated, positively related to serum creatinine
values at baseline and highly reproducible during the two
paired infusion periods. Dopamine reduced renal vascular
resistance in patients without ARF (median RI/PI from 0.70
to 0.65/1.20 to 1.07, Po0.01) but increased resistance
indices in patients with ARF (median RI/PI from 0.77 to
0.81/1.64 to 1.79, Po0.01) in the absence of effects on
systemic hemodynamics. Subgroup analysis of patients with
ARF revealed that dopamine induced renal vasoconstriction
above 55 years (n¼ 22) and in patients not receiving
norepinephrine (n¼ 20). In conclusion ‘low-dose’ dopamine
can worsen renal perfusion in patients with ARF, which adds
to the rationale for abandoning the routine use of ‘low-dose’
dopamine in critically ill patients.
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Dopamine is an endogenous catecholamine that influences
different catecholamine receptors in a dose-dependent
manner. Infusion rates of 2–5 mg/kg min induce primarily
dopaminergic effects, whereas at rates above 5mg/kg min
b-adrenergic effects predominate and a-adrenergic actions
gradually become more important. For more than three
decades, the so-called ‘low-dose’ dopamine (o5mg/kg min)
has been widely used in intensive care patients for presumed
renal protective effects. The rationale for this application is
based on findings in healthy humans and experimental
animals, where ‘low-dose’ dopamine was found to cause renal
vasodilatation associated with an increase in renal blood flow
and diuresis.1–5 Additional evidence suggested that the
infusion of dopamine may blunt endogenous norepinephrine-
induced vasoconstriction.6,7 These effects are thought to be
mediated by stimulation of (i) dopamine-1 receptors in the
renal vasculature,8,9 (ii) dopamine-2 receptors inhibiting
norepinephrine release from presynaptic nerve endings,8,10,11
and (iii) dopamine-1 and -2 receptors in tubular cells
inhibiting Naþ /Kþ ATPase activity and thereby inducing
natriuresis.8,12 Larger doses of dopamine are thought to
augment renal blood flow chiefly by increasing cardiac
output.13–15
Several clinical trials have meanwhile investigated the use
of ‘low-dose’ dopamine for the prevention of acute renal
failure (ARF) in patients at risk, as well as its therapeutic use
in patients with established ARF. Some of these studies have
shown that dopamine increases urine output,3,5,16–19 whereas
others found no effect.20–22 A prospective, randomized
controlled trial by the Australian and New Zealand Intensive
Care Society group found that low-dose dopamine does not
prevent or reverse ARF, nor does it improve outcome.20 The
largest retrospective analysis also failed to show a beneficial
effect of ‘low-dose’ dopamine on survival or the need of
hemodialysis in patients with ARF.23–25 In view of these data,
reviewers concluded that the use of ‘low-dose’ dopamine
cannot be recommended.1 On the other hand, given the
heterogeneity of ICU patient populations, lack of evidence
does not necessarily imply evidence of absence of an effect in
all patient subgroups. In order to circumvent problems of
patient heterogeneity and to obtain further evidence for the
effect of ‘low-dose’ dopamine on renal blood flow under
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different clinical circumstances, we measured renal perfusion
indices in a placebo-controlled crossover design in patients
on a medical ICU with and without ARF.
RESULTS
Patient characteristics
Given the setting of a general medical ICU, the spectrum of
diseases was broad and, as expected, it differed between
patients with and without ARF. The primary diagnosis of
patients without ARF included cardiothoracic surgery with
protracted recovery (n¼ 2), gastrointestinal bleeding (n¼ 2),
postresuscitation syndrome (n¼ 1), acute coronary syn-
drome (n¼ 1), near drowning (n¼ 1), heart failure (n¼ 1),
complicated urinary tract infection (n¼ 1), and pneumo-
thorax (n¼ 1). Two of these patients were ventilated.
In contrast, 73% of the patients with ARF were ventilated.
Their primary diagnosis were sepsis (n¼ 5), pancreatitis
(n¼ 3), cholangitis (n¼ 1), pneumonia (n¼ 3), heart failure
(n¼ 3), liver failure (n¼ 2), cardiothoracic surgery (n¼ 2),
endocarditis (n¼ 1), intracerebral infarction (n¼ 3), rhabdo-
myolysis (n¼ 1), opiate intoxication (n¼ 1), gastrointestinal
bleeding (n¼ 2), postresuscitation syndrome (n¼ 1), necro-
tizing fasziits (n¼ 1), and partial occlusion of iliac arteries
(n¼ 1). Baseline characteristics of all patients are shown in
Table 1. As expected, patients with ARF had significantly
higher serum creatinine and urea concentrations as com-
pared to patients without ARF. Eleven patients
with ARF were oligo-anuric (daily urine volume o500 ml).
Mean RI and PI were higher in patients with ARF, reflec-
ting increased renal vascular resistance. Moreover, there was a
positive, nonlinear relationship between renal resistance
indices and the degree of renal failure, as determined by
the serum creatinine value (Figure 1). Blood pressure was
not different between patients with and without ARF. In
patients receiving norepinephrine, the heart rate was
higher, but other baseline parameters were not different
(Figure 1 and Table 1).
Correlation and reproducibility of resistance measurements
Measurements of RI and PI were closely correlated with each
other during each treatment period (Figure 2), and
comparison of renal resistance between groups using either
RI and PI always gave identical results. Moreover, it turned
out that the measurements of both indices at the end of both
Table 1 | Baseline characteristics of study patients
ARF
No ARF (n=10) Without norepinephrine (n=20) With norepinephrine (n=10)
Age (years) 54715.0 61714.3 62714.1
Sex 5 m, 5 w 11 m, 9 w 6 m, 4 w
Systolic BP (mmHg) 127726 130723 120723
Diastolic BP (mmHg) 63716 63717 69717
Mean arterial pressure (mmHg) 88717 86718 87716
Heart rate (beats/min) 83716.1 81714.3 100722.1**
Mechanical ventilation 1 12 10
Duration of ICU stay before study (days) 7.577.1 7.274.6 5.775.7
Serum urea (mg/dl) 39.979.6 128.3750.5* 109.8756.7*
Serum creatinine (mg/dl) 0.770.3 3.472.0* 2.570.5*
RI 0.6970.08 0.8170.07* 0.7570.05*
PI 1.2070.27 1.9270.51* 1.6770.40*
ARF, acute renal failure; BP, blood pressure; ICU, intensive care unit.
Values are means7s.d.
*Significant difference between the two patient groups with and without ARF (acute renal failure) (Po0.001; Mann–Whitney)
**indicates significant difference in patients treated with norepinephrine as compared to the two other groups (P=0.03).
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Figure 1 | Relationship between the baseline RI and serum
creatinine in all patients. NE, norepinephrine.
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Figure 2 | Correlation between the baseline RI and PI in all
patients.
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placebo and dopamine periods were highly reproducible
(Figure 3) and not different from each other. For subsequent
analysis, the arithmetic mean was therefore calculated for the
placebo and the dopamine period, respectively, and used for
comparisons between groups.
Effects of dopamine on renal perfusion indices
‘Low-dose’ dopamine resulted in measurable effects on renal
perfusion indices both in patients with and without ARF, but
the effect occurred in the opposite direction (Figure 4).
In patients without ARF, dopamine decreased median RI
from 0.70 to 0.65 (Po0.01) and PI from 1.20 to 1.07
(Po0.01). In marked contrast, in patients with ARF, RI
increased significantly under dopamine infusion (median
RI from 0.77 to 0.81; Po0.01; median PI from 1.64 to 1.79;
Po0.01).
Considering the patients with ARF receiving and not
receiving norepinephrine separately, dopamine increased
resistance indices significantly in the absence of nor-
epinephrine (median RI from 0.79 to 0.82 and median PI
from 1.69 to 1.84; Po0.01), whereas there was no effect in
patients treated with norepinephrine (median RI 0.75 vs 0.75,
median PI 1.54 vs 1.58) (Figure 5).
Renal vascular resistance is known to increase with
age,26,27 and we also observed a weak correlation between
RI/PI and age in patients with and without ARF (not shown).
In order to investigate if age had an influence on the effect of
dopamine on renal resistance, data were analyzed separately
for patientso55 years andX55 years. As shown in Figure 6,
the decrease in renal resistance in patients without ARF was
absent in older patients and the increase in RI in patients
with ARF only occurred in patients X55 years.
Effects of dopamine on systemic hemodynamics and urine
production
The observed effects of ‘low-dose dopamine’ on renal
perfusion occurred in the absence of systemic hemodynamic
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Figure 3 | Percentage change of RI compared to baseline value
after first and second dopamine infusion. A close linear relation-
ship between both values (r¼ 0.74, Po0.0001) indicates
high reproducibility of the effect of dopamine.
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Figure 4 | Intraindividual comparison and mean7s.d. of RI values
during placebo and dopamine infusion in patients with and
without ARF. In patients without ARF dopamine reduced the RI
significantly (Po0.01, Wilcoxon test), whereas there was a significant
increase in patients with ARF (Po0.01).
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Figure 5 | Effect of dopamine on RI values in patients with and
without norepinephrine (NE) infusion.
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Figure 6 | Effect of dopamine on RI values in patients below or
above 55 years. * and 1 indicate outliers.
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effects (Table 2); heart rate and systolic, diastolic, and mean
blood pressure were not significantly different between
dopamine and placebo infusion periods (Wilcoxon test).
Effects of dopamine on urine output and electrolyte
excretion are given in Table 3. There were no differences
between urine flow and the amount of sodium, potassium,
creatinine, or urea excreted per hour between the placebo or
dopamine administration, neither in patients with ARF nor
in those without ARF.
DISCUSSION
Although previous discussions on the therapeutic value of
‘low-dose’ dopamine focused on the lack of effect of
dopamine and potential adverse effects outside the kidneys,
this study is to our knowledge the first to demonstrate
that dopamine may actually deteriorate renal perfusion in
patients with ARF.
Hypoperfusion is considered to play a significant role in
the pathogenesis of ARF and can arise from either a decrease
in renal perfusion pressure or an increase in renal vascular
resistance. Importantly, renal vascular resistance increases,
even when systemic vascular resistance is low, as in sepsis.28
In line with this concept, we found a significant elevation of
RI in the renal cortex in patients with ARF as compared to
intensive care patients not fulfilling ARF criteria. This
increase was reversible and disappeared in parallel with a
decline of serum creatinine during the recovery phase of ARF
(data not shown).
The rationale for the use of dopamine for preservation of
renal function is based on findings in healthy humans and
experimental animals, where it increases renal blood flow.1–5
In a previous study, also using Doppler flow measurements,
Stevens et al.29 showed that ‘low-dose’ dopamine reduces
renal vascular resistance in intensive care patients without
ARF. Confirming these data, we also observed a decline of RI
and PI in this patient group. However, in marked contrast, RI
and PI increased in patients with ARF (Figure 4), thus
indicating a further deterioration of renal perfusion in the
presence of acute renal injury. The application of norepi-
nephrine was not part of our study protocol, but 10 patients
received norepinephrine as part of their therapy. When
analyzing patients treated with and without norepinephrine
separately, the deterioration of renal perfusion appeared to be
confined to those patients not on norepinephrine, but given
the small sample size this conclusion needs to be drawn with
care. In contrast to observations in healthy volunteers7
however, we could not detect an improvement in renal
perfusion when ‘low-dose’ dopamine was added to norepi-
nephrine (Figure 5).
We did not study the functional significance of the
reduction in renal perfusion in ARF patients, but if renal
hypoperfusion and subsequent ischemic injury play a
dominant role in the perpetuation of renal failure, this effect
of dopamine might well increase tubular damage and retard
recovery. Our findings are consistent in this respect with a
previous study inferring detrimental effects of ‘low-dose’
dopamine on renal tubular integrity from increased urinary
excretion of retinol binding protein.30
Animal studies also found that the effect of ‘low-dose’
dopamine on renal perfusion may vary depending on
circumstances and that a vasodilatation occurs under baseline
conditions, but not in sepsis,31 or in animals with ischemic,
postischemic, or gylcerol-induced ARF.32,33 Although our
findings in patients go beyond these observations in showing
Table 2 | Hemodynamic parameters during placebo and dopamine infusion
No ARF (n=10) ARF without norepinephrine (n=20) ARF with norepinephrine (n=10)
Placebo Dopamine Placebo Dopamine Placebo Dopamine
Heart rate (beats/min) 82716 83711 84714 87717 104726 102729
Systolic BP (mmHg) 122723 123722 129717 134723 110723 123723
Diastolic BP (mmHg) 60714 6077 61713 62713 6378 64710
Mean arterial pressure (mmHg) 81716 81710 85715 84713 78710 84713
Values are means7s.d.
ARF, acute renal failure; BP, blood pressure.
Table 3 | Urine and electrolyte excretion during placebo and dopamine infusion
No ARF (n=7) ARF
Without norepinephrine (n=11) With norepinephrine (n=4)
Urine values Placebo Dopamine Placebo Dopamine Placebo Dopamine
Urine output (ml/h) 106794 1567145 125776 1547142 1407148 1127105
Sodium (mmol/h) 10.973.4 15.2710.2 10.175.8 11.579.7 15.1710.5 11.974.9
Potassium (mmol/h) 5.372.6 5.072.2 3.872.4 4.473.5 4.571.7 3.671.8
Creatinine (g/h) 0.0970.04 0.0870.05 0.0370.02 0.0570.05 0.0770.05 0.0670.04
Urea (g/h) 1.570.4 1.970.8 1.270.14 1.672.5 1.271.1 0.970.5
Values are means7s.d. In none of the three groups of patients were any of the parameters significantly different between the placebo and the dopamine period. In three
patients without ARF (acute renal failure) and in four patients with ARF, urine collection during the study periods was inaccurate, because patients had no bladder catheters
and their values were therefore not included.
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that dopamine may even worsen renal perfusion, the
pathophysiological basis for the difference of dopamine
effects remains unclear. As established acute tubular necrosis
is characterized by an imbalance between renal vasoconstric-
tors and vasodilators, it is possible that the effect of
dopamine varies depending on the array of vasoactive
substances co-influencing renal resistance.34 Alternatively,
despite identical infusion rates of dopamine, its local
concentration in the kidney could be higher in patients with
ARF owing to endogenous production of dopamine35 and/or
reduced renal clearance.36 As the vascular effects of dopamine
are dose-dependent, with vasoconstrictive actions becoming
more important with increasing concentrations, an increase
in dopamine concentrations could theoretically account for a
change in its net effect. Noteworthy, however, systemic
hemodynamics were unaffected in all patient groups in this
study (Table 2), suggesting that if an accumulation of
dopamine does play a role, it would mainly be local.
Interestingly, we also found an association of patient age
with the effects of dopamine on renal perfusion. The
vasodilatation in the absence of ARF was more marked in
the younger patient group, and dopamine-induced vasocon-
striction tended to be more pronounced in elderly patients
(Figure 6). Other studies also found an age-dependent
increase in renal vascular resistance26,27 and revealed that
dopamine-induced renal vasodilatation was blunted with
increasing baseline resistance and age.4 As the average age of
intensive care patients is increasing, this observation under-
scores the clinical relevance of the observed adverse effect of
dopamine on renal perfusion.
Different effects of dopamine on vascular resistance are
not only of interest in single vascular beds, but also in
comparison between different organs. In particular, potential
vasoconstrictive effects of the so-called ‘low-dose’ dopamine
in the splanchnic circulation are of concern1 and they may
promote bacterial translocation. In addition, there is also evi-
dence that ‘low-dose’ dopamine through mechanisms that
are poorly understood can also suppress the ventilatory
drive.37
A limitation of this study is its focus on renal
hemodynamic effects of ‘low-dose’ dopamine. Since recently,
there is renewed interest in potential non-hemodynamic
tissue protective effects of dopamine, following the observa-
tion that the use of ‘low-dose’ dopamine in organ donors is
associated with improved outcomes of renal transplants.38
However, this finding was not made in all studies,39
prospective data supporting a beneficial effect of dopamine
in this setting are not yet available, and the impact of
potential immunomodulatory functions in the intensive
care population is unpredictable. Given the failure to
demonstrate a benefit of ‘low-dose’ dopamine in preventing
or ameliorating incipient or established renal damage in
intensive care patients, we believe that our data, by showing
the potential of dopamine to reduce renal perfusion,
add strongly to the rationale to discontinue its use in
critically ill patients.
MATERIALS AND METHODS
Patients
Forty patients treated on a medical ICU were included: 10 patients
(five male and five female patients) without ARF and 30 patients (17
male and 13 female patients) with ARF. Ten patients with ARF
required treatment with norepinephrine (median 1.271.0 mg/h)
independent of study medication. ARF was defined as an increase in
serum creatinine above 2.0 mg/dl or twice the baseline value in the
absence of preexisting chronic renal failure. Patients with ARF were
only included when the onset of ARF occurred less than10 days ago.
Study protocol
Renal perfusion indices were measured by Doppler ultrasonography
using a randomized, double-blind, placebo-controlled crossover
design. Dopamine at a dose of 2 mg/kg min in NaCl 0.9% or placebo
(isovolemic 0.9% NaCl) was given by continuous intravenous
infusion in alternating sequence for four subsequent periods of
60 min, starting randomly with either dopamine or placebo
(Figure 7).
All measurements were performed by one investigator who was
blinded with respect to the sequence of dopamine and placebo in
each patient, using a Hitachi EBU 525 ultrasound machine with a
3.75 MHz convex-array transducer. Each patient’s right or left
kidney was selected for study depending on ease of access. After
visualizing the kidney in gray scale and color Doppler mode and
verification of the absence of signs of chronic renal damage, an
interlobar or arcuate artery was selected and measured with pulse
wave Doppler. At least three readings per measurement were taken
from the same artery. The same artery was restudied after each
60 min period. Doppler spectra were analyzed for PI ((peak systolic
frequency shiftminimum diastolic frequency shift)/mean fre-
quency shift) and RI ((peak systolic frequency shiftminimum
diastolic frequency shift)/peak systolic frequency shift). Measure-
ments of heart rate, arterial pressure, and urine output were
recorded hourly and a urine sample for analysis of electrolytes,
creatinine, and urea excretion was taken after each hour. When
patients were treated with intermittent dialysis, the measurements
were scheduled with at least a 15-h interval between the end of the
dialysis and the start of Doppler measurements. Patients on conti-
nuous hemofiltration were investigated while the hemofiltration was
ongoing.
The local ethics committee approved the study protocol and
written informed consent was obtained from the patient or next
of kin.
Statistical analysis
All results in the same patient were considered as paired
observations, with each patient serving as his or her own control.
The significance of differences was analyzed by the non-parametric
Wilcoxon test for two related samples, and to test for significant
Randomization
60 min
1 2 3 4 5
Dopamine (2 g/kg/min) 
Placebo (NaCl 0.9%) 
Perfusion
measurements 
Figure 7 | Schematic presentation of the study design. All patients
received ‘low-dose’ dopamine or placebo for two periods of 1 h in
alternating sequence and were randomly assigned to two groups
receiving either dopamine or placebo first.
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differences between different groups, the non-parametric Mann–
Whitney test was used. A P-value of less than 0.05 was considered as
statistically significant. To examine the relation between the RI, PI, and
other patient variables, the correlation after Spearman between the
baseline values of RI or PI was determined, thus excluding the
influence of dopamine. SPSS was used for data analysis and calculation.
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